News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Afternoon Grant,
Looks like Kinetic has put in a short-term bottom. Today's move today, so far, is impressive...
Grant,
Technically, KCI showing signs the downward momentum is changing relative to the intermediate-term trend.
- Positive divergence between price trend and the trends of the Force Index/MFI/+DI. This suggests accumulation taking place.
- Downward momentum is starting to lessen. This can be seen on RSI, volume trend, -DI trend, Full Sto, and ChiOsc. Since "mo" changes before price, price should soon follow.
Will be a good buying opportunity like ARAY was a few weeks ago...
Very nice gain this past year...
|
Followers
|
1
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
29
|
|
Created
|
07/22/07
|
Type
|
Free
|
| Moderators | |||
Company Background
Kinetic Concepts, Inc. (KCI) is a global medical technology company that manages advanced wound care and therapeutic surfaces. The Company designs, manufactures, markets and services a range of products, which incude advanced wound healing and tissue repair; pulmonary care and post cardiac arrest complications in the intensive care unit (ICU); bariatric care, and wound treatment and prevention. The advanced wound care systems incorporate the V.A.C. Therapy technology. Its therapeutic surfaces, including specialty hospital beds, mattress replacement systems and overlays, are designed to address pulmonary complications associated with immobility. KCI has an infrastructure designed to meet the specific needs of medical professionals and patients across all healthcare settings, including acute care hospitals, extended care organizations and patients' homes, both in the United States and abroad.
Company Contact
Address 8023 Vantage Drive
San Antonio, TX 78230
Telephone (210) 524-9000
Fax
Website http://www.kci1.com/
VAC Wound Therapy
Science behind the VAC improving granulation tissue and wound healing -- MICRODEFAMATION
Science behind the VAC improving wound healing by "shrinking" wounds -- MACRODEFAMATION
HISTOLOGY OF WOUNDS: VAC vs. GAUZE DRESSINGS IN JOSEPH'S ARTICLE
PICTURE PROGRESSION OF A PATIENT'S WOUND MANAGEMENT FROM AN ARTICLE ON ORTHOPEDIC TRAUMA AND USE OF THE WOUND VAC (from Thompson et al, OTA Mtg, 2002):
KCI Kinetic Therapy for Pulmonary Disease (Adult Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI) etc.)
Website http://www.kci1.com/276.asp
(this last website gives more information on the Rotoprone Kinetic therapy for Pulmonary disease)
These are new devices that improve lung function in the severely injured or ill patient with Pulmonary problems such as ARDS and ALI
KCI also produces beds for improving the pulmonary system of spinal cord injured patients.
Research and Development New Therapies:
Better By Design
Introducing the InfoV.A.C.® and ActiV.A.C.® Therapy Systems.
The InfoV.A.C.® Therapy System has been designed to make using V.A.C.® Therapy even easier and to keep Health Care Professionals more informed about their patients’ progress. Learn more about InfoV.A.C.® Therapy.
The ActiV.A.C.® Therapy System has been designed to make it easier for patients to resume their activities of daily living while helping to provide and document proper V.A.C.® Therapy usage. Learn more about ActiV.A.C.® Therapy.
http://www.kci1.com/2461.asp
From website www.MedTech1.com a KCI sponsored website:
KCI USA, Inc.
8023 Vantage Drive
PO Box 659508
San Antonio, TX 78230-4769
United States
Phone: (877)-WOUNDVAC
Fax: (210)-255-6998
http://www.woundvac.com
This information is intended for users in the United States only. V.A.C.® Therapy is available in some foreign jurisdictions. For more information please contact 1-877-WOUNDVAC or contact your local KCI representative.
V.A.C.® (Vacuum Assisted ClosureTM) Therapy - An Advanced System for Wound Healing What is V.A.C.® Therapy?
MiniV.A.C.®
"V.A.C.®" is short for Vacuum Assisted ClosureTM. V.A.C. Therapy is a system that uses controlled negative pressure (vacuum) to help promote wound healing. Clinical studies demonstrate that V.A.C. Therapy also helps remove infectious materials and other fluids from the wound. V.A.C. Therapy is currently delivered in three models, the V.A.C., the MiniV.A.C.®, and the new V.A.C. ATS models.
V.A.C.ATS
How does V.A.C.® Therapy work?
The V.A.C.® Therapy System consists of a computer-controlled therapy unit, canister, sterile plastic tubing, foam dressing, and clear V.A.C. drape dressing. The foam dressing is placed into the wound. One end of the tube is connected to the foam, the other end to a canister that connects to the V.A.C. control unit. The wound area is sealed with the clear V.A.C. drape, similar to a large bandage. The V.A.C. system pulls infectious materials and other fluids from the wound through the tube and collects them inside the canister.
Who is a candidate for V.A.C.® Therapy?
V.A.C.® Therapy application
V.A.C.® Therapy may be prescribed for the following conditions:
Chronic open wounds (diabetic and pressure ulcers)
Acute and traumatic wounds
Meshed grafts
Subacute wounds (i.e. dehisced incisions)
Flaps
V.A.C.® Therapy is contraindicated in:
Fistulas other than enteric or blind fistulas
Necrotic tissue with eschar present
Osteomyelities (untreated)
Malignancy in the wound
Do not place V.A.C. dressing over exposed blood vessels or organs.
V.A.C.® Therapy precautions*:
Active bleeding
Difficult wound hemostasis
Patients on anticoagulants
Follow universal precautions
When placing the V.A.C. dressing in proximity to blood vessels or organs, take care to ensure that they are adequately protected with overlying fascia, tissue, or other protective barriers. Greater care should be taken with respect to weakened, irradiated, sutured blood vessels or organs. Bone Fragments or sharp edges could puncture a barrier, vessel or organ.
Wounds having enteric fistulas may require special precautions to optimize healing.
*Always consult the Care and Safety Tips section of the V.A.C.® Quick Reference Guide before placing the V.A.C.® on a patient.
Check with your health care provider if you think V.A.C. Therapy might be right for you. V.A.C. Therapy is restricted to sale or rental only upon the order of a licensed physician.
More detailed information about V.A.C.® Therapy
The V.A.C.® (Vacuum Assisted ClosureTM) assists in wound closure by applying localized negative (sub-atmospheric) pressure to help promote wound healing. Vacuum pressure is applied to a special dressing positioned in the wound cavity or over a flap or graft. This pressure-distributing wound packing helps remove fluids from the wound and promote the normal healing process.
V.A.C. Therapy uses an open-cell reticulated foam that can be cut to the shape of the wound(s), or can be placed side by side or layered to treat very large wounds. A tube embedded in the foam allows the application of vacuum pressure for the removal of excess wound fluid . The dressing and distal evacuation tube are covered by a transparent, occlusive drape that provides a seal which allows the application of vacuum pressure to the system.
The free end of the evacuation tube is attached to a canister reservoir which fits into a microprocessor-controlled vacuum unit and collects the fluids drawn away from the wound. The vacuum unit provides continuous or intermittent negative pressure selected to meet the needs of the wound being treated. The pressure can be adjusted within a range that has been demonstrated to provide optimal fluid removal without placing the delicate wound tissue at risk of injury.
The application of V.A.C. Therapy to a wound provides a moist wound-healing environment. A moist wound-healing environment is the standard of care for wound healing. Removal of excess interstitial fluid also can lead to removal of excess proteinases present in the periwound environment. Metalloproteinases are known to bind and degrade growth factors before the growth factor can reach its target tissue. With inhibitors removed, growth factors can stimulate cell proliferation and migration. Removal of excess interstitial fluid can naturally help decrease periwound induration (swelling) further helping to promote wound healing.
The evacuation of air from the open cells of the foam causes the foam to collapse on itself and provide a mechanical distraction, or stretching, of the soft tissues.
V.A.C. Therapy offers many benefits of high technology in one system. The standard dressing change routine of every 48 hours (12 hours for infected wounds) can result in less disturbance to the wound and improved patient comfort.
V.A.C.®, MiniV.A.C.®, V.A.C.ATS, Vacuum Assisted Closure and other trademarks designated herein are property of its affiliates and licensees. The V.A.C., MiniV.A.C. and V.A.C. ATS systems are subject to patents.
Company meeting of shareholders May 2007
http://library.corporate-ir.net/library/64/645/64595/items/247556/Form2007Proxy.pdf
Company Report 2006
http://library.corporate-ir.net/library/64/645/64595/items/232888/Form10-K2006.pdf
KCI is added to Standard and Poor's Midcap 400 INDEX
http://investor.kci1.com/phoenix.zhtml?c=64595&p=irol-newsArticle&ID=1075179&highlight=
NEW INFORMATION: KCI buys LifeCell Corporation
This is a great move for KCI. Synergistic products and LifeCell is well-run company. Here is some analysts reports on the subject from SeekingAlpha:
Status Report: LifeCell - Kinetic Concepts
by The M & A Researcher
The purchase of LifeCell Corporation (LIFC) looks like a fairly routine acquisition by Kinetic Concepts Inc. (KCI) from a regulatory and timing standpoint, although the products/services involved certainly are not routine. LIFC is in the business of creating and selling human tissue repair/replacement products derived directly from human and animal soft tissue. This is obviously a relatively new industry in terms of public availability, and as such the markets for LIFC's products have not fully been established at this point. The company quite obviously competes with a variety of companies that offer a wide range of alternative approaches to soft tissue repair.
Listed in LIFC's annual report are the following competitors:
Our tissue matrix products compete with synthetic surgical mesh products marketed by such large medical device companies as Johnson Johnson; C.R. Bard; W.L. Gore Associates; and Integra Life Sciences Holdings Corporation. They also compete with animal-derived products marketed by companies such as C.R. Bard; Cook, Inc.; and Tissue Science Laboratories, plc. Two tissue processors, Musculoskeletal Transplant Foundation [“MTF] and Tutogen, distribute human tissue-based products that compete with our products. MTF distributes its products through a direct sales force and through Synthes, Inc. and Johnson Johnson. Tutogen distributes its products through C.R. Bard and Mentor.
Our AlloCraft DBM product competes with other similar bone repair products produced by companies such as Regeneration Technologies, Inc.; Osteotech, Inc.; AlloSource; Wright Medical Group; Isotis Orthobiologics; and MTF.
This is purely a vertical move for KIC, which specializes in wound and tissue repair and after care via non-living tissue processes. Although the products are somewhat similar in a broad sense, the companies respective products are quite different -- KIC does not offer living-tissue products -- and address different physical treatment areas. Even if the companies did actually have directly competing, overlapping niche products, this combination probably would not draw much regulatory interest due to the variety of alternatives currently on the market.
In short, KCI should be able to complete this transaction in well under 60 days, and probably very close to a 45-day time frame.
KCI Board Rules:
Please follow iHub rules for posting.
Please keep posts on topic & related to this company.
It is understandable that regular posters on the board will now and then WANT to share insight on other stocks possibly of mutual interest... but the board focus IS not to be a "tip exchange site" so habitual posting of that nature should be taken to other appropriate boards, done by PM (if premium members), or by email.
DISCLAIMER - Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information contained herein.
